常山药业艾本那肽注射液减重适应症获批临床

Group 1 - The demand for weight loss drugs is rapidly increasing due to the rising prevalence of obesity and related metabolic diseases [1] - Changshan Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of Aibennate injection for weight loss indications, potentially providing new treatment options for obesity patients [1] - Aibennate is a long-acting GLP-1 receptor agonist developed using DACTM technology, which combines chemically modified Exenatide with recombinant human serum albumin to form a new stable compound [1] Group 2 - If Aibennate is successfully launched, it will reduce the company's heavy reliance on heparin business, enhance profitability and risk resistance, and accelerate the transformation potential of the company's innovative R&D platform [2] - The drug must complete subsequent clinical trials and receive approval from the National Medical Products Administration before it can be marketed [2]